Chapter Ten - The Pharma Hydra

CHAPTER TEN

The Pharma Hydra

PURDUE WASN’T THE only one taking notes.

As OxyContin printed billions and transformed pain into product, the rest of Big Pharma watched and learned. The success wasn’t just the drug. It was the strategy. And in corporate America, strategy scales.

Soon, Purdue wasn’t alone.

Janssen launched Nucynta.
Endo pushed Opana.
Teva rolled out generic oxycodone.
Insys introduced a fentanyl spray, and some executives encouraged reps to misrepresent cancer diagnoses to boost sales.

Each company adopted some version of Purdue’s blueprint.

Minimize addiction risks.
Maximize dosages.
Incentivize doctors.
Target vulnerable communities.
Delay regulation.
Blame the patient.

The opioid market exploded. By the mid-2000s, the U.S. was consuming 80% of the world’s opioids with less than 5% of the population. Pain became a trillion-dollar industry. And as overdose deaths soared, so did shareholder returns.

Purdue wasn’t concerned. If anything, they welcomed the noise.

The more companies involved, the harder it was to pin blame on any single one. The narrative got fuzzy. The lawsuits got complicated. The crisis got crowded.

And the Sacklers?

They acted like bystanders.

As public outrage grew, they claimed Oxy was just a piece of a larger problem. They pointed fingers at doctors, patients, illicit heroin, Mexican cartels, and Chinese fentanyl. Anything to keep attention off the origin point.

They framed themselves as the first responders to a crisis they created.

They even funded anti-addiction groups and public health campaigns. PR masquerading as penance. It was brand management dressed up as civic duty.

Meanwhile, the companies that followed Purdue’s model faced their own scandals. Insys executives were sent to prison. Johnson & Johnson paid massive fines. Teva and Allergan faced waves of lawsuits. But the damage was already done.

The genie wasn’t just out of the bottle.
The bottle had become a business model.

And every pill was another head on the hydra.

Cut one off, and two more took its place.

This wasn’t just Purdue’s crisis anymore.
It was America’s industry-wide infection.